
USA - NYSE:AGN -
The current stock price of AGN is 193.02 null. In the past month the price increased by 5.94%. In the past year, price increased by 37.71%.
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Allergan Plc
CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK
DUBLIN L2 D17 E400
CEO: Brenton L. Saunders
Phone: 862-261-7000
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
The current stock price of AGN is 193.02 null. The price increased by 0.02% in the last trading session.
Allergan Plc (AGN) has a dividend yield of 1.53%. The yearly dividend amount is currently 2.96.
AGN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
AGN stock is listed on the New York Stock Exchange, Inc. exchange.
Allergan Plc (AGN) has a market capitalization of 63.50B null. This makes AGN a Large Cap stock.
ChartMill assigns a technical rating of 9 / 10 to AGN. When comparing the yearly performance of all stocks, AGN is one of the better performing stocks in the market, outperforming 92.42% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to AGN. While AGN is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months AGN reported a non-GAAP Earnings per Share(EPS) of 17.64. The EPS increased by 5.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -15.44% | ||
| ROA | -2.81% | ||
| ROE | N/A | ||
| Debt/Equity | 0.31 |